RAJKUMAR VENKATRAMANI to Rhabdomyosarcoma
This is a "connection" page, showing publications RAJKUMAR VENKATRAMANI has written about Rhabdomyosarcoma.
Connection Strength
8.872
-
Children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone treated on Children's Oncology Group studies. Pediatr Blood Cancer. 2024 Oct; 71(10):e31200.
Score: 0.744
-
Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group. Lancet Oncol. 2024 Jul; 25(7):912-921.
Score: 0.742
-
Prognosis of children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone marrow treated on Children's Oncology Group studies. Pediatr Blood Cancer. 2023 Dec; 70(12):e30701.
Score: 0.704
-
Management and outcomes of chest wall rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Pediatr Blood Cancer. 2023 07; 70(7):e30357.
Score: 0.682
-
Patients with completely resected nongenitourinary low-risk embryonal rhabdomyosarcoma are candidates for reduced duration low-intensity chemotherapy. Cancer. 2022 12 01; 128(23):4150-4156.
Score: 0.659
-
An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials. Pediatr Blood Cancer. 2022 04; 69(4):e29511.
Score: 0.628
-
Comment on: Patients with nonmetastatic embryonal rhabdomyosarcoma arising in the biliary tract should be treated on low-risk clinical trials. Pediatr Blood Cancer. 2022 07; 69(7):e29554.
Score: 0.623
-
Suboptimal outcome for patients with biliary rhabdomyosarcoma treated on low-risk clinical trials: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 04; 68(4):e28914.
Score: 0.585
-
Late Events Occurring After 5?Years in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2025 Jan; 72(1):e31421.
Score: 0.190
-
Outcomes for patients with perineal and perianal rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Pediatr Blood Cancer. 2024 Nov; 71(11):e31303.
Score: 0.188
-
Roadmap for the next generation of Children's Oncology Group rhabdomyosarcoma trials. Cancer. 2024 Nov 15; 130(22):3785-3796.
Score: 0.185
-
Event-free survival in relapsed and refractory rhabdomyosarcoma treated on cooperative group phase II trials: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2024 Jul; 71(7):e31009.
Score: 0.183
-
Germline Genetic Testing and Survival Outcomes Among Children With Rhabdomyosarcoma: A Report From the Children's Oncology Group. JAMA Netw Open. 2024 03 04; 7(3):e244170.
Score: 0.181
-
Adolescents and young adults with rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatr Blood Cancer. 2024 Apr; 71(4):e30847.
Score: 0.180
-
Children's Oncology Group's 2023 blueprint for research: Soft tissue sarcomas. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30556.
Score: 0.173
-
Germline genetic variants and pediatric rhabdomyosarcoma outcomes: a report from the Children's Oncology Group. J Natl Cancer Inst. 2023 06 08; 115(6):733-741.
Score: 0.172
-
Impact of race and ethnicity on presentation and outcomes of patients treated on rhabdomyosarcoma clinical trials: A report from the Children's Oncology Group. Cancer Med. 2023 06; 12(11):12777-12791.
Score: 0.171
-
Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta-analysis. Cancer Med. 2023 05; 12(9):10222-10229.
Score: 0.170
-
Rhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatr Blood Cancer. 2023 06; 70(6):e30293.
Score: 0.169
-
Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. J Clin Oncol. 2023 05 01; 41(13):2382-2393.
Score: 0.168
-
Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group. Clin Cancer Res. 2023 01 17; 29(2):364-378.
Score: 0.168
-
Pediatric rhabdomyosarcoma incidence and survival in the United States: An assessment of 5656 cases, 2001-2017. Cancer Med. 2023 02; 12(3):3644-3656.
Score: 0.163
-
Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. Eur J Cancer. 2022 09; 172:367-386.
Score: 0.162
-
Congenital spindle cell rhabdomyosarcoma: An international cooperative analysis. Eur J Cancer. 2022 06; 168:56-64.
Score: 0.159
-
Deep Learning of Rhabdomyosarcoma Pathology Images for Classification and Survival Outcome Prediction. Am J Pathol. 2022 06; 192(6):917-925.
Score: 0.159
-
Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group. Pediatr Blood Cancer. 2022 06; 69(6):e29644.
Score: 0.158
-
Metabolic response as assessed by 18 F-fluorodeoxyglucose positron emission tomography-computed tomography does not predict outcome in patients with intermediate- or high-risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Cancer Med. 2021 02; 10(3):857-866.
Score: 0.145
-
Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Cancer. 2021 03 15; 127(6):946-956.
Score: 0.144
-
Local therapy to distant metastatic sites in stage IV rhabdomyosarcoma. Pediatr Blood Cancer. 2018 Feb; 65(2).
Score: 0.117